ライフサイエンスコーパス: fluoromisonidazole

1 lead hypoxia tracers, (64)Cu-ATSM and (18)F-fluoromisonidazole.

2 luation of tumor hypoxia with agents such as fluoromisonidazole.

3 ed with other hypoxia tracers, such as (18)F-fluoromisonidazole.

4 with PET/MRI using the hypoxia tracers (18)F-fluoromisonidazole ((18)F-FMISO) and (18)F-fluoroazomyci

5 ng of tumor hypoxia and perfusion with (18)F-fluoromisonidazole ((18)F-FMISO) dynamic PET (dPET) in h

6 ed pharmacokinetic analysis of (18)F-labeled fluoromisonidazole ((18)F-FMISO) dynamic PET to assist t

7 guide radiotherapy, can be imaged with (18)F-fluoromisonidazole ((18)F-FMISO) hypoxia PET.

8 (18)F-fluoromisonidazole ((18)F-FMISO) is the most widely used

9 ty-three GBM patients were assessed by (18)F-fluoromisonidazole ((18)F-FMISO) PET and conventional an

10 (18)F-fluoromisonidazole ((18)F-FMISO) PET is a noninvasive, q

11 mor perfusion and hypoxia with dynamic (18)F-fluoromisonidazole ((18)F-FMISO) PET may allow for an im

12 of tumor hypoxia quantified by dynamic (18)F-fluoromisonidazole ((18)F-FMISO) PET/CT and the risk of

13 -fluoro-2-deoxy-d-glucose ((18)F-FDG), (18)F-fluoromisonidazole ((18)F-FMISO), and 3'-deoxy-3'-(18)F-

14 lood volume (rCBV) maps, and uptake of (18)F-fluoromisonidazole ((18)F-FMISO), respectively.

15 ctivity of 4 hypoxia PET radiotracers ((18)F-fluoromisonidazole [(18)F-FMISO], (18)F-flortanidazole [

16 ng the uptake of 3 tracers ((18)F-FDG, (18)F-fluoromisonidazole [(18)F-FMISO], and (18)F-fluoride) in

17 Fluorine 18-labeled fluoromisonidazole ([18F]FMISO), a PET tracer that under

18 -bis(N(4)-methylthiosemicarbazone) and (18)F-fluoromisonidazole; amino acids for PET imaging, includi

19 ody molds, injected intravenously with (18)F-fluoromisonidazole, and imaged dynamically for 105 min.

20 N4-methylthiosemicarbazone) (ATSM) and (18)F-fluoromisonidazole are trapped only at extreme levels of

21 ne whether kinetic analysis of dynamic (18)F-fluoromisonidazole data provides better discrimination o

22 Using single-session 45-min shortened (18)F-fluoromisonidazole dPET datasets appears to be adequate

23 editing the clinical implementation of (18)F-fluoromisonidazole dPET protocols.

24 scan, each patient underwent a 45-min (18)F-fluoromisonidazole dPET scan, followed by 10-min acquisi

25 Ninety-minute (18)F-fluoromisonidazole dPET scans were acquired in animals.

26 g using shortened acquisition times in (18)F-fluoromisonidazole dPET, with the goal of expediting the

27 (18)F-fluoromisonidazole dynamic PET (dPET) is used to identif

28 d the biodistributions of [18F]FETA and [18F]fluoromisonidazole (FMISO) at 2 and 4 h postinjection in

29 -thymidine for cellular proliferation, (18)F-fluoromisonidazole (FMISO) for tissue hypoxia, and (11)C

30 ed tomography (CT) using the radiotracer 18F-Fluoromisonidazole (FMISO) has been widely employed to i

31 PET images and radiosensitivity from [(18)F]fluoromisonidazole (FMISO) PET images.

32 Tumor hypoxia on 18F-fluoromisonidazole (FMISO) positron emission tomography

33 with tumor viability of fluorine 18 ((18)F) fluoromisonidazole (FMISO) uptake in hepatocellular carc

34 Fluoromisonidazole (FMISO), labeled with the positron em

35 th GBM were imaged preoperatively with (18)F-fluoromisonidazole (FMISO)-PET and serial gadolinium-enh

36 Bq bolus of each candidate tracer (and (18)F-fluoromisonidazole for comparative purposes) was injecte

37 Cardiac retention of (18)F-fluoromisonidazole increased from 0.44% +/- 0.17% during

38 bazone) (Cu-PTSM) and the hypoxic tracer 18F-fluoromisonidazole (MISO).

39 ighted MRI (T2), and hypoxia assessed by 18F-fluoromisonidazole PET (18F-FMISO).

40 (18)F-fluoromisonidazole PET, a noninvasive means of identifyi

41 Animals underwent (18)F-fluoromisonidazole positron emission tomographic and (18

42 (18)F-fluoromisonidazole positron emission tomographic imaging

43 F-labelled fluoromisonidazole positron emission tomography imaging

44 A baseline (18)F-fluoromisonidazole positron emission tomography scan was

45 Furthermore, the (18)F-fluoromisonidazole signal was high at the early stages.

46 (18)F-fallypride and (18)F-fluoromisonidazole, two well-established PET radioligand

47 n tomographic imaging corroborated the (18)F-fluoromisonidazole uptake by the aorta of atheroscleroti

48 The dynamic (18)F-fluoromisonidazole uptake data were fitted with 2 varian

49 were assessed by immunohistochemistry.(18)F-fluoromisonidazole uptake increased with time on diet (s

50 (18)F-fallypride and (18)F-fluoromisonidazole were successfully synthesized.